LD-2 disclosure · 1st Quarter - Report
AMGEN USA INC.
Client
- Name
- AMGEN USA INC.
- Description
- Biotechnology company.
- Location
- District of Columbia · United States of America
Registrant
- Description
- ​Government affairs and consulting firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesPharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
LobbyistsMONICA POPP · HAZEN CLAY MARSHALL
Covered position (MONICA POPP): Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
Covered position (HAZEN CLAY MARSHALL): Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA)
Copyright/Patent/Trademark
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
LobbyistsMONICA POPP · HAZEN CLAY MARSHALL